All In Biotech

Drug Trial Radar · NCT02469155

A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment

A Randomized, Double-Blind, Placebo- and Active-Controlled, Multi-Center Study to Assess the Antipsychotic Efficacy of ITI-007 After 6 Weeks of Treatment in Patients With Schizophrenia

Last checked: Nov 20, 2026Latest source record: Oct 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 696 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

696

Actual

Start

Jun 2015

Primary completion

Aug 2016

Study completion Aug 2016

Sponsor

Lead sponsor
Intra-Cellular Therapies, Inc.Industry
Sponsor type
Industry
First posted
Jun 11, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will evaluate the antipsychotic efficacy of ITI-007 in a randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study in patients diagnosed with schizophrenia having an acute exacerbation of psychosis.

Conditions

  • Schizophrenia

Interventions

  • ITI-007Drug

  • RisperidoneDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total ScoreTime frame: 6 weeks

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Site

    Little Rock, Arkansas

  • Clinical Site

    Springdale, Arkansas

  • Clinical Site

    Culver City, California

  • Clinical Site

    Lemon Grove, California

  • Clinical Site

    Long Beach, California

  • Clinical Site

    San Diego, California

  • Clinical Site

    North Miami, Florida

  • Clinical Site

    Berlin, New Jersey

  • Clinical Site

    Marlton, New Jersey

  • Clinical Site

    Austin, Texas

  • Clinical Site

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.